Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition
We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E<sub>2</sub> synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group. A focused virtual library of 1 × 10<sup>4</sup> molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 and, among them, two items featured IC<sub>50</sub> values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound 3b, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for 3b; on the other hand, compound 7e exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether moiety possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of 7e and 7d, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells. These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.
Authors
- Tania Ciaglia (ORCID: https://orcid.org/0000-0002-6592-4373)
- Katrin Fischer (ORCID: https://orcid.org/0000-0001-5278-3949)
- Carmine Ostacolo (ORCID: https://orcid.org/0000-0003-3715-8680)
- Maria Grazia Ferraro (ORCID: https://orcid.org/0000-0002-3022-1205)
- Manuela Giovanna Basilicata (ORCID: https://orcid.org/0000-0003-2736-1044)
- Giuseppe Bifulco (ORCID: https://orcid.org/0000-0002-1788-5170)
- Michele Manfra (ORCID: https://orcid.org/0000-0002-3320-972X)
- Oliver Werz (ORCID: https://orcid.org/0000-0002-5064-4379)
- Carlo Irace (ORCID: https://orcid.org/0000-0002-5172-4573)
- R. Hofstetter (ORCID: https://orcid.org/0000-0002-1077-9703)
- Giacomo Pepe (ORCID: https://orcid.org/0000-0002-7561-2023)
- Silvana Pedatella (ORCID: https://orcid.org/0000-0002-4078-1468)
- Mauro De Nisco (ORCID: https://orcid.org/0009-0001-9410-3072)
- Alessia Bertamino (ORCID: https://orcid.org/0000-0002-5482-6276)
- Pietro Campiglia (ORCID: https://orcid.org/0000-0002-1069-2181)
- Marialuisa Piccolo (ORCID: https://orcid.org/0000-0002-8908-4532)
- Gianluigi Lauro (ORCID: https://orcid.org/0000-0001-5065-9717)
- Maria Giovanna Chini (ORCID: https://orcid.org/0000-0002-3943-5883)
- Michela Aliberti
- Anella Saviano
Institutions
- University of Molise (IT)
- University of Salerno (IT)
- University of Basilicata (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Institute of Genetics and Biophysics (IT)
- University of Naples Federico II (IT)
- Friedrich Schiller University Jena (DE)
Publication Details
- Journal
- European Journal of Medicinal Chemistry
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1016/j.ejmech.2025.117402
- Citations
- 3
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Associazione Italiana per la Ricerca sul Cancro